ArticleBMC gastroenterology2026
Association of neutrophil-to-high-density lipoprotein ratio with all-cause mortality among individuals with non-alcoholic fatty liver disease: the NHANES database prospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a global public health crisis linked to elevated all-cause and cardiovascular mortality. The neutrophil-to-high-density lipoprotein ratio (NHR) is an emerging inflammatory-lipid biomarker that integrates systemic inflammation and lipid dysregulation. However, its prognostic value for long-term mortality in NAFLD remains undetermined.
methodsWe conducted a population-based prospective cohort study using data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. A total of 5,320 participants diagnosed with NAFLD were enrolled and divided into four groups according to quartiles of NHR (Q1-Q4). Multivariate Cox regression, restricted cubic spline, threshold effect, and subgroup analyses were used to evaluate the association between NHR and all-cause mortality.
resultsDuring a mean follow-up of 9.2 years, 1,172 all-cause deaths and 392 cardiovascular disease (CVD) deaths were documented. In the fully adjusted Cox models, higher NHR was significantly associated with elevated risks of all-cause mortality (HR = 1.27, 95% CI: 1.02-1.57) and CVD mortality (HR = 2.15, 95% CI: 1.44-3.22) in a dose-response manner, but not with cancer mortality. Further adjustment for blood lipids and hepatic function markers did not materially alter the results, supporting the robustness of the observed associations. Threshold and spline analyses further revealed a significant nonlinear relationship between NHR and all-cause mortality, with an inflection point of 2.072, when NHR was equal to or above 2.072, each 1-unit increase was associated with an 8% elevation in all-cause mortality risk (HR = 1.08, 95% CI: 1.04-1.12, P < 0.001). Subgroup stratified analyses were performed as exploratory analyses. Although the association between elevated NHR and all-cause mortality reached statistical significance within several individual subgroups, no significant multiplicative interaction was detected for any stratifying factor, indicating no meaningful effect modification across these population strata.
conclusionElevated NHR is independently associated with an increased risk of all-cause and cardiovascular mortality in NAFLD patients. NHR may serve as a simple, inexpensive, and readily available prognostic biomarker for risk stratification and clinical management in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.